Sheng Hu Selected Research

camrelizumab

5/2024	Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
2/2024	First-line treatment with camrelizumab plus famitinib in advanced or metastatic NSCLC patients with PD-L1 TPS ≥1%: results from a multicenter, open-label, phase 2 trial.
1/2022	On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.
1/2022	Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sheng Hu Research Topics

Disease

61	Neoplasms (Cancer) 05/2024 - 11/2010
10	Lung Neoplasms (Lung Cancer) 10/2022 - 03/2017
9	Stomach Neoplasms (Stomach Cancer) 01/2024 - 10/2004
9	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2023 - 01/2021
8	Neoplasm Metastasis (Metastasis) 08/2023 - 01/2019
8	Cognitive Dysfunction 05/2023 - 06/2016
7	Brain Ischemia (Cerebral Ischemia) 03/2024 - 01/2009
7	Inflammation (Inflammations) 05/2023 - 05/2012
6	Hepatocellular Carcinoma (Hepatoma) 05/2024 - 08/2007
6	Adenocarcinoma of Lung 08/2023 - 11/2020
5	Liver Neoplasms (Liver Cancer) 05/2024 - 03/2017
5	Hypoxia (Hypoxemia) 12/2023 - 01/2021
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2022 - 01/2020
5	Infarction (Infarctions) 12/2017 - 02/2005
4	Prostatic Neoplasms (Prostate Cancer) 12/2023 - 10/2016
4	Carcinogenesis 11/2023 - 01/2020
4	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 11/2023 - 01/2009
4	Colorectal Neoplasms (Colorectal Cancer) 10/2023 - 10/2019
4	Breast Neoplasms (Breast Cancer) 01/2023 - 06/2016
4	Hyperplasia 12/2022 - 12/2010
4	Infections 03/2022 - 11/2005
3	Disease Progression 08/2023 - 01/2022
3	Colonic Neoplasms (Colon Cancer) 11/2022 - 01/2020
3	Reperfusion Injury 04/2022 - 01/2009
2	Pulmonary Hypertension 12/2023 - 01/2022
2	Ischemic Stroke 11/2023 - 10/2019
2	COVID-19 05/2023 - 10/2020
2	Hepatolenticular Degeneration (Wilson's Disease) 04/2023 - 01/2023
2	Obesity 01/2023 - 01/2021
2	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/2023 - 01/2019
2	Cough 09/2022 - 01/2018
2	Acute Kidney Injury (Acute Renal Failure) 01/2022 - 01/2019
2	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 08/2021 - 01/2021
2	Fever (Fevers) 06/2021 - 03/2017
2	Colitis 01/2021 - 03/2017

Drug/Important Bio-Agent (IBA)

10	Proteins (Proteins, Gene)FDA Link 12/2023 - 10/2016
10	Biomarkers (Surrogate Marker)IBA 12/2023 - 01/2012
8	Cisplatin (Platino)FDA LinkGeneric 01/2023 - 11/2010
5	Immune Checkpoint InhibitorsIBA 05/2024 - 01/2021
5	EnzymesIBA 01/2024 - 04/2011
5	Messenger RNA (mRNA)IBA 11/2023 - 11/2005
4	CytokinesIBA 05/2024 - 08/2022
4	camrelizumabIBA 05/2024 - 01/2022
4	Glucose (Dextrose)FDA LinkGeneric 11/2023 - 10/2019
4	Circular RNAIBA 11/2023 - 04/2021
4	apelin-13 peptideIBA 05/2023 - 01/2022
4	Programmed Cell Death 1 ReceptorIBA 02/2023 - 01/2021
3	Mechanistic Target of Rapamycin Complex 1IBA 12/2023 - 01/2022
3	MicroRNAs (MicroRNA)IBA 12/2023 - 11/2022
3	Oxygen (Dioxygen)IBA 11/2023 - 05/2012
3	CateninsIBA 11/2023 - 01/2019
3	Indicators and Reagents (Reagents)IBA 01/2023 - 10/2020
3	Fluorouracil (Carac)FDA LinkGeneric 11/2022 - 01/2022
3	Monoclonal AntibodiesIBA 07/2022 - 01/2019
3	LigandsIBA 01/2022 - 11/2010
3	Sevoflurane (Ultane)FDA LinkGeneric 11/2012 - 10/2009
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 05/2024 - 02/2024
2	famitinibIBA 05/2024 - 02/2024
2	Angiogenesis InhibitorsIBA 05/2024 - 01/2022
2	ginsenoside RdIBA 03/2024 - 04/2022
2	LuciferasesIBA 01/2024 - 02/2019
2	TOR Serine-Threonine KinasesIBA 12/2023 - 01/2022
2	nimotuzumabIBA 12/2023 - 01/2019
2	ErbB Receptors (EGF Receptor)IBA 12/2023 - 08/2023
2	ChemokinesIBA 11/2023 - 12/2021
2	Dimethyl Sulfoxide (DMSO)FDA LinkGeneric 10/2023 - 05/2011
2	CholesterolIBA 10/2023 - 01/2018
2	Pemetrexed (MTA)FDA Link 08/2023 - 01/2022
2	Amino Acids FDA Link 08/2023 - 01/2016
2	VaccinesIBA 05/2023 - 11/2016
2	tislelizumabIBA 02/2023 - 01/2023
2	LeptinIBA 01/2023 - 01/2021
2	B7-H1 AntigenIBA 01/2023 - 07/2022
2	NucleotidesIBA 01/2023 - 04/2022
2	rezivertinibIBA 01/2023 - 11/2022
2	Interleukin-6 (Interleukin 6)IBA 11/2022 - 10/2020
2	AcidsIBA 09/2022 - 11/2005
2	Immunotoxins (Immunotoxin)IBA 07/2022 - 01/2022
2	InflammasomesIBA 04/2022 - 01/2022
2	C-Reactive ProteinIBA 03/2022 - 04/2021
2	GlypicansIBA 01/2022 - 01/2021
2	apatinibIBA 01/2022 - 01/2022
2	Therapeutic UsesIBA 01/2022 - 01/2021
2	Transcription Factors (Transcription Factor)IBA 12/2021 - 01/2012
2	Hyaluronic Acid (Hyaluronan)IBA 08/2021 - 01/2021
2	GelatinIBA 08/2021 - 01/2021
2	HydrogelsIBA 08/2021 - 01/2021
2	carboxymethyl-chitosanIBA 08/2021 - 01/2021
2	LipidsIBA 01/2021 - 03/2017
2	Cadherins (E-Cadherin)IBA 01/2021 - 05/2019
2	Telomerase (Telomerase Reverse Transcriptase)IBA 01/2021 - 01/2019
2	DNA (Deoxyribonucleic Acid)IBA 11/2020 - 10/2004

Therapy/Procedure

26	Therapeutics 05/2024 - 11/2010
10	Drug Therapy (Chemotherapy) 12/2023 - 06/2016
9	Immunotherapy 01/2023 - 03/2017
3	Chinese Traditional Medicine (Traditional Chinese Medicine) 11/2023 - 01/2021
3	Oncolytic Virotherapy 11/2022 - 05/2018
2	Electroacupuncture 03/2024 - 08/2022
2	Radiotherapy 08/2023 - 01/2022
2	Microspheres (Microsphere) 08/2021 - 01/2021